title: Synthetic Cannabinoids.
abstract: Synthetic cannabinoids (SCBs), also known under the brand names of "Spice," "K2," "herbal incense," "Cloud 9," "Mojo" and many others, are becoming a large public health concern due not only to their increasing use but also to their unpredictable toxicity and abuse potential. There are many types of SCBs, each having a unique binding affinity for cannabinoid receptors. Although both Δ-tetrahydrocannabinol (THC) and SCBs stimulate the same receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), studies have shown that SCBs are associated with higher rates of toxicity and hospital admissions than is natural cannabis. This is likely due to SCBs being direct agonists of the cannabinoid receptors, whereas THC is a partial agonist. Furthermore, the different chemical structures of SCBs found in Spice or K2 may interact in unpredictable ways to elicit previously unknown, and the commercial products may have unknown contaminants. The largest group of users is men in their 20s who participate in polydrug use. The most common reported toxicities with SCB use based on studies using Texas Poison Control records are tachycardia, agitation and irritability, drowsiness, hallucinations, delusions, hypertension, nausea, confusion, dizziness, vertigo and chest pain. Acute kidney injury has also been strongly associated with SCB use. Treatment mostly involves symptom management and supportive care. More research is needed to identify which contaminants are typically found in synthetic marijuana and to understand the interactions between different SBCs to better predict adverse health outcomes.
authors.affiliation: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
authors.forename: Brooke
authors.initials: B
authors.lastname: Mills
authors.forename: Andres
authors.initials: A
authors.lastname: Yepes
authors.forename: Kenneth
authors.initials: K
authors.lastname: Nugent
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D063386:Cannabinoid Receptor Agonists / Q000009:adverse effects*; D002186:Cannabinoids / Q000009:adverse effects*; D002637:Chest Pain / Q000139:chemically induced; D015198:Designer Drugs / Q000009:adverse effects*; D013759:Dronabinol / Q000009:adverse effects*; D006212:Hallucinations / Q000139:chemically induced*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007508:Irritable Mood; D011595:Psychomotor Agitation / Q000209:etiology; D019966:Substance-Related Disorders / Q000453:epidemiology*; D013610:Tachycardia / Q000139:chemically induced*; D014717:Vertigo / Q000139:chemically induced
chemical_list: D063386:Cannabinoid Receptor Agonists; D002186:Cannabinoids; D015198:Designer Drugs; D013759:Dronabinol